Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5346 tablets and will conduct clinical trials in the near future.

HRS-5346 is an oral small molecule inhibitor of Lp (a), showing the potential to prevent the risk of atherosclerotic cardiovascular disease by effectively reducing Lp (a). Oral administration is also expected to provide greater convenience for patients. According to inquiries, there are currently no similar drugs approved for marketing at home or abroad. Up to now, the total R&D investment for HRS-5346 film-related projects is approximately RMB 86.2 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.